ArticleHuman vaccines & immunotherapeutics2016
The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Cost-effectiveness modeling for gender-neutral human papillomavirus vaccines: A systematic literature review.Human vaccines & immunotherapeutics · 2025Pooled it
- Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review.PloS one · 2020Pooled it
- Parents' uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies.BMJ open · 2018Pooled it
- Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.The Journal of infectious diseases · 2018Trial
- Article
- Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong.Human vaccines & immunotherapeutics · 2023Article
- The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong.Cost effectiveness and resource allocation : C/E · 2021Article
- HPV vaccine for men: Where to? (Review).Experimental and therapeutic medicine · 2021Review
- Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.BMC infectious diseases · 2021Article
- Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.Frontiers in pharmacology · 2021Article
- Intersectoral cooperation to increase HPV vaccine coverage: an innovative collaboration between Managed Care Organizations and state-level stakeholders.Human vaccines & immunotherapeutics · 2020Article
- HPV vaccination bridges to HPV screening.EClinicalMedicine · 2020Article
- Article
- Excess Cancer Cases and Medical Costs Due to Suboptimal Human Papillomavirus Vaccination Coverage in California.Sexually transmitted diseases · 2019Article
- Review of the economic evidence presented to the United States Advisory Committee on Immunization Practices, 2012-2016.Vaccine · 2019Article
- Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States.Human vaccines & immunotherapeutics · 2019Review
- Incident genital HPV infections and potential impact of HPV vaccines in adult women living with HIV/AIDS.Human vaccines & immunotherapeutics · 2019Article
- Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.Human vaccines & immunotherapeutics · 2019Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe objective of this study was to assess the incremental costs and benefits of the 9-valent HPV vaccine (9vHPV) compared with the quadrivalent HPV vaccine (4vHPV). Like 4vHPV, 9vHPV protects against HPV types 6, 11, 16, and 18. 9vHPV also protects against 5 additional HPV types 31, 33, 45, 52, and 58.
methodsWe adapted a previously published model of the impact and cost-effectiveness of 4vHPV to include the 5 additional HPV types in 9vHPV. The vaccine strategies we examined were (1) 4vHPV for males and females; (2) 9vHPV for females and 4vHPV for males; and (3) 9vHPV for males and females. In the base case, 9vHPV cost $13 more per dose than 4vHPV, based on available vaccine price information.
resultsProviding 9vHPV to females compared with 4vHPV for females (assuming 4vHPV for males in both scenarios) was cost-saving regardless of whether or not cross-protection for 4vHPV was assumed. The cost per quality-adjusted life year (QALY) gained by 9vHPV for both sexes (compared with 4vHPV for both sexes) was < $0 (cost-saving) when assuming no cross-protection for 4vHPV and $8,600 when assuming cross-protection for 4vHPV.
conclusionsCompared with a vaccination program of 4vHPV for both sexes, a vaccination program of 9vHPV for both sexes can improve health outcomes and can be cost-saving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.